Health & Bio
Regenxbio's RGX-202 Phase 3 trial hits primary endpoint
The AFFINITY DUCHENNE study met its primary endpoint on May 14. Two serious adverse events reported; CEO remains confident in FDA approval prospects.
Primary sources · 2
The AFFINITY DUCHENNE study met its primary endpoint on May 14. Two serious adverse events reported; CEO remains confident in FDA approval prospects.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.